Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab: Editorial comment

Samir S. Taneja

Research output: Contribution to journal › Comment/debate › peer-review

Fingerprint

Dive into the research topics of 'Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab: Editorial comment'. Together they form a unique fingerprint.